LDLksi

LDLksi is an acronym used in lipidology to denote an emerging biomarker related to low-density lipoprotein (LDL) particles. It is not a single molecule but a composite score intended to capture qualitative features of LDL, such as particle number, size distribution, oxidation, and binding propensity to arterial walls. The term has appeared in a limited set of studies as researchers seek markers of LDL particle quality beyond traditional LDL-C measurements.

Measurement and interpretation: Because there is no universal definition, LDLksi is calculated using different inputs across studies. Common components include LDL particle number (LDL-P) measured by NMR, average particle size, oxidized LDL levels, and apolipoprotein B. Some schemes also incorporate functional assays of LDL oxidation. There is no standardized method or clinical cutoff, and routine laboratory testing is not widely available.

Clinical relevance: Early data suggest higher LDLksi may associate with greater atherosclerotic risk and could refine risk stratification when used with standard lipid panels. However results are preliminary, replication is limited, and there is no consensus on prognostic value or treatment implications. Major guidelines currently do not endorse LDLksi.

Status and history: The concept emerged in the late 2010s as researchers studied LDL particle heterogeneity. It remains mainly a research construct with limited use in specialized laboratories.

See also: Low-density lipoprotein, LDL particle number, apolipoprotein B, oxidized LDL.